Tuesday, May 12, 2026

AFFF and Philips CPAP Dockets Anchor 234-Case Federal Mass-Tort Surge

Federal mass-tort dockets logged 234 new filings on May 11, 2026, paced by mature environmental and medical-device litigation. Environmental Litigation Group PC executed the day's dominant block, registering 118 new AFFF Litigation (MDL 2873) cases — a single-firm pipeline-clearing alleging that exposure to per- and polyfluoroalkyl substances in aqueous film-forming foams caused cancer and environmental contamination. Dicello Levitt LLP mounted a 42-case offensive in the Philips CPAP Litigation (MDL 3014), pressing claims that recalled sleep apnea devices contained sound-abatement foam that degraded into toxic particles and produced respiratory damage and carcinogenic effects.

The Talcum Powder Litigation (MDL 2738) drew 21 new cases coordinated across four plaintiffs' firms — The Miller Firm LLC led with 8, followed by Ashcraft Gerel LLP (6), Pulaski Kherkher PLLC (4), and Rosen Injury Lawyers (3) — continuing the longstanding asbestos-contamination claim against Johnson & Johnson talc. The newly formed Depo-Provera Litigation (MDL 3140) attracted 10 new complaints from a consortium of mass-tort heavyweights led by Morgan & Morgan PA (3), Johnson Law Group (2), and Napoli Shkolnik (2), alleging the contraceptive injection causes meningiomas and intracranial tumors. Rounding out the top five, Frantz Law Group APLC single-handedly filed 10 new Social Media Addiction Litigation (MDL 3047) complaints alleging algorithmic design defects in major platforms cause severe psychological harm to minors.

EPA Deregulation Push Reshapes Ethylene Oxide Sterilization Liability Landscape

The U.S. EPA's pending proposal to weaken ethylene oxide emission standards continues to draw scientific and community pushback into May, sharpening the evidentiary stakes for plaintiffs in the Sterigenics and B. Braun EtO sterilization-facility dockets. A peer-reviewed risk assessment published in PubMed on April 30, 2026, modeled EtO release from a representative sterilization facility into surrounding communities and concluded that documented emissions correlate with elevated lifetime cancer risk well above EPA benchmarks — bolstering plaintiffs' specific-causation arguments in pending state and federal suits. Tampa Bay Times reporting on May 4, 2026, mapped active EtO emissions near residential neighborhoods, while Chemical & Engineering News documented more than two dozen scientists publicly urging EPA not to relax the existing emissions rule. The convergence of fresh community-health data with a federal-rulemaking pivot toward looser standards is expected to feature in dispositive briefing across the EtO sterilization caseload, where defendants are increasingly relying on regulatory-compliance defenses to rebut state-law tort claims.

New Wrongful Death Lawsuit Accelerates GLP-1 Gastroparesis Litigation

On May 11, 2026, a wrongful death lawsuit against Novo Nordisk escalated the stakes in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation (MDL 3094). The complaint was filed by the husband of a 76-year-old woman who died from complications related to severe gastroparesis, alleging that her use of Ozempic caused the life-threatening stomach paralysis. The plaintiff asserts that the manufacturer failed to adequately warn patients and physicians about the severity and potential long-term implications of gastrointestinal side effects associated with the drug. The filing adds critical severity to a federal docket that has already grown to roughly 3,636 pending actions before Judge Karen S. Marston in the Eastern District of Pennsylvania. As the MDL proceeds through its discovery phase, this wrongful death claim highlights the escalating liability risks for manufacturers ahead of scheduled mid-2026 Science Day proceedings.